Galectin Therapeutics Executive Chairman, James
Czirr to Appear on “The RedChip Money Report” on FOX Business News
James Czirr, Executive Chairman of Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, will be a guest on “The RedChip Money Report”™ television program featuring emerging growth companies on FOX Business News, Saturday, February 9, 2013 at 2:30 p.m. Eastern.
“The RedChip Money Report”™ delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies. The show is hosted by Dave Gentry, a leading authority on small-cap stocks and president of RedChip, an international small-cap research firm and an Inc. 5000 company. The program airs in a paid programming block with the network http://www.redchip.com/media/mediamain.asp?page=redchiptv&pl=PLgBW00-WEinAN4lnGanOG7hEJALqRJzAi&from=services .
WHO: James Czirr, Executive Chairman, Galectin Therapeutics
WHAT: FOX Business News “The RedChip Money Report”
WHEN: Saturday, February 9, 2013, 2:30 PM, Eastern
About Galectin Therapeutics
Galectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com .